HA35 inhibits TLR4 signaling by decreasing importin α5 and increasing Tollip, which results in the inhibition of alcohol-induced liver injury in rodents.80,81 Thus, HA35 may be a treatment option for TLR4-mediated liver disease progression. Here, TLR4 is linked to liver disorder.